@seanong.bsky.social takes to the next level analysis of the BALANCE trial (7 vs 14 days of antibiotics) and impact of protocol non-adherence (there was about 20% non-adherence to protocol durations). Read his thread and read his paper! @thelancetinfdis.bsky.social @thedohertyinst.bsky.social

Want to come work on SNAP, BALANCE+, and STRAP? And change how we treat and manage bloodstream infections? See below. #IDSky

Great to speak with @thelancetinfdis.bsky.social together with @gurujosh.bsky.social about adaptive platform trials in infectious diseases!

We’re kicking off #Antimicrobials2026 with Symposium 1: Staphylococcus aureus, featuring two outstanding speakers. 💊 Prof @steventong.bsky.social SNAP Update 🧬 Prof Anton Y. Peleg Daptomycin and MRSA Register now: www.antimicrobials.com.au #MRSA #idsky #amssky #clinmicrosky

🆕🔥🔥CloCeBa RCT Cloxacillin versus cefazolin for MSSA Bacteraemia Cefazolin has a non-inferior efficacy regarding mortality, microbiological or clinical endpoints and was associated with a lower rate of serious adverse events #IDSky www.thelancet.com/journals/lan...

International funding flows in infectious diseases clinical trials published in selected high-impact journals over a 10-year period New paper in @cmijournal.bsky.social, led by @seanong.bsky.social. See thread for details. @thedohertyinst.bsky.social @unimelb.bsky.social #IDSky

Free access to our article on the inclusion of LMICs in platform trials of bloodstream infections. SNAP in Johannesburg. @steventong.bsky.social @gurujosh.bsky.social authors.elsevier.com/a/1lVzy,RGPg...

Glad to have the opportunity to collaborate with Spanish colleagues on this. We conducted a pooled Bayesian post-hoc analysis of the BACSARM and SAFO trials evaluating combination therapy with fosfomycin for SAB. The door may not be closed on adjunctive fosfomycin! Justifies need for more RCTs.

The Staphylococcus aureus Network Adaptive Platform (SNAP) trial has been nominated for a Patient healthcare communication award! Public voting is now open 👉 ccrew.accesscr.com.au/cpir-2025/pu... Find out more about SNAP 🔗 www.snaptrial.com.au Give us a vote!! @thedohertyinst.bsky.social

Thrilled to share our new research led by Jane Davies @menziesresearch.bsky.social on First Nations people in the NT living with chronic hepatitis B. An important study that could inform better care: doi.org/10.1186/s128... #idsky #MedSky #HepSky #LiverSky

Thankful for another opportunity to write this editorial with @steventong.bsky.social in @jama.com: jamanetwork.com/journals/jam... We discuss this trial, which evaluated the impact of different recruitment letter formats on RCT enrolment: jamanetwork.com/journals/jam...

Tuberculosis (TB), an infectious disease caused by bacteria, was responsible for as many as one-quarter of all deaths in the US and Europe during parts of the 18th and 19th centuries. However, as we see in the chart for England and Wales, deaths from TB have declined dramatically in rich countries.

Our review on hierarchical composite endpoints (HCEs) has just been published in @cidjournal.bsky.social: doi.org/10.1093/cid/... We provide a conceptual overview of HCEs, explain the different associated target parameters and analytic methods. @steventong.bsky.social @gurujosh.bsky.social

Dr K Gibney flys the flag for 🦘 clin trials by 🎺 ISAAC 🔎 at Abx prophylaxis of close iGAS contacts (enrolling soon) STRAP 🔎 backbone Abx, adjunctive Abx, and IVIg (enrolling 2026ish) Only enrolling in Aus for now but looking for int. collab. #LISSSD25 #idsky #clinicaltrials #strep

Kick off the new season with our latest issue. 😄

Have joined a Push-Up challenge to raise awareness and funds for mental health. 3,214 push-ups in 23 days. www.thepushupchallenge.com.au/fundraiser/s...

Exciting to see this new adaptive platform trial! For pregnant women and people who are at risk of preterm birth, and babies born preterm. PLATIPUS (Platform for Adaptive Trial in Perinatal UnitS) @platipus.bsky.social @drbretty.bsky.social First domains will be: PROMOAT and BabyCINO

Always a privilege to write with @seanong.bsky.social!

Cefazolin vs Antistaphylococcal Penicillins for Treatment of Methicillin-Susceptible Staphylococcus aureus Bacteremia: A Systematic Review & Meta-Analysis @connorprosty.bsky.social @seanong.bsky.social &c Cefaz more effective, safer #idsky www.clinicalmicrobiologyandinfection.com/article/S119... 🔓

🆕💫 Systematic Review and Meta-Analysis 30 observational studies( SNAP & CloCeBa not included) N: 3869 Cefazolin versus Antistaphylococcal Penicillins for the Treatment of MSSA Bacteremia #idsky www.clinicalmicrobiologyandinfection.com/article/S119...

Our new paper in @cmijournal.bsky.social, a systematic review where we evaluated reporting of baseline sociodemographic characteristics across 1343 ID clinical trials over a 10-year period. A 🧵: @steventong.bsky.social #IDSky doi.org/10.1016/j.cm...

such a joy to discuss PSSA/MSSA domains of SNAP. incredible work led by @gurujosh.bsky.social @steventong.bsky.social conversation w/ the fabulous @angelahuttner.bsky.social joint effort @escmid.bsky.social Communicable & @sidpharm.bsky.social Breakpoints podcast podcasts.apple.com/us/podcast/s...

🆕 Episode of #Breakpoints/Communicable: Breakpoints joins forces w @cmicomms.bsky.social podcast to discuss the highly anticipated SNAP trial updates presented at ESCMID Global 2025. Listen to Breakpoints: sidp.pinecast.co | breakpoints-sidp.org Listen to Communicable: communicable.transistor.fm

🎙️ Just published a new episode of #Communicable: "SNAP out of it" In first collaboration with #Breakpoints, we unpack new results from the S. aureus SNAP trial platform with @gurujosh.bsky.social & @steventong.bsky.social. Listen here: #IDSky #Clinmicro #MedSky #PharmSky

🎙️ This Sunday evening (US)/Monday morning (CET): the first joint #Breakpoints & #Communicable episode 🌏 @erinmccreary.bsky.social & @angelahuttner.bsky.social host @gurujosh.bsky.social & @steventong.bsky.social to discuss the #SNAP trial's first results #IDSky #MedSky communicable.transistor.fm

Stay tuned for the first @cmicomms.bsky.social & #Breakpoints collaboration episode on Sun, May 4th 6PM US EST/Mon May 5th 12 AM CET. Hosts Angela Huttner & Erin McCreary interview SNAP trial investigators, Steven Tong &Joshua Davis, on PSSA and MSSA domain results shared at 2025 ESCMID Global.

The first #Communicable & #Breakpoints collaboration episode drops Mon 5 May! Hosts @angelahuttner.bsky.social & @erinmccreary.bsky.social interview SNAP trial investigators, @steventong.bsky.social & Joshua Davis, on the results shared at #ESCMIDGlobal 2025. #IDSky #clinmicro @sidpharm.bsky.social

Please apply if your interested in running a new adaptive platform trial for invasive Streptococcal infections. Will work closely with the #SNAP_trial team. @thedohertyinst.bsky.social Applications close May 20 2025. jobs.unimelb.edu.au/en/job/92003...

🙍‍♀️ w/Staph aureus BSI have high rates of mortality & metastatic infx (Think ❤️,🫁,🦴, & 🔩!). Huge shout out to these authors for succinctly summarizing A LOT of complex data! Truly a huge 🏋️‍♂️ 👀 Figure 2 & Table 2 doi.org/10.1001/jama.2025.4288 #IDSky #rxsky #pharmsky #AMSsky #medsky #SIDP

nothing I'd rather wake up at 5am to do than talk to @angelahuttner.bsky.social (while she's vacationing in Greece!) & @steventong.bsky.social @gurujosh.bsky.social in Australia about SNAP Trial results presented at #ECSMIDGlobal Joint Communicable/Breakpoints episode dropping on May 5th!! #idsky

Thanks @paulsaxmd.bsky.social for highlighting the SNAP trial! @thedohertyinst.bsky.social @asidaud.bsky.social @gurujosh.bsky.social

Calling all statisticians: we need your help. We'll soon be running an RCT comparing ceftazidime + iv fosfomycin to ceftaz alone in septic patients. Our hospital's stats unit is small & overworked. If you're available to freelance, we have a budget for this! #IDSky #Clinmicro #EpiSky #MedSky (1/2)

SNAP is extending from S aureus to invasive streptococcal infections! A new platform trial for iGAS and iSDSE @gurujosh.bsky.social @joshosowicki.bsky.social @drmichaelmarks.bsky.social www.doherty.edu.au/news-events/...

Juliane Bubeck Wardenburg keynote lecture at #ESCMIDGlobal on Staphylococcus aureus and alpha toxin and host response hla well described toxin, but also modulates host T cell response to S. aureus so that immune response is attenuated SSTI and even colonisation may lead to this modulation

Interesting data Barista showing diversity in S. aureus isolates from sterile sites. Some evidence isolates become enriched for mutations over time. Wonder if really evolution over time or if samples from deeper sites would differ at baseline from those in blood? @steventong.bsky.social #ESCMID2025

Fabulous talk @seanong.bsky.social Used BALANCE data developed & validated multi-variable risk scores which accurately predict outcome bacteramia. Showed results hold true across all risk groups. Paper: www.thelancet.com/journals/ecl... #ESCMID2026 @steventong.bsky.social @drtoddlee.bsky.social

Congratulations to Steve Tong, Josh Davis and the huge SNAP team (including Monash Health). Clear outcome that cefazolin is less nephrotoxic than flucloxacillin for MSSA, and pencillin is better for PSSA. @steventong.bsky.social @gurujosh.bsky.social

@steventong.bsky.social presents the results of the PSSA domain of the SNAP 🫰 trial - the worlds largest trial of staph aureus bacteremia - at #ESCMID2025 fluclox resulted in higher mortality and more AKI compared to penicillin for PSSA

Josh, one of your subversive/sassy T-shirts will do 😊 📣 Hall 13 everyone, in an hour go #clinicaltrials in #IDSky!! 💪 #ESCMIDGlobal

Remember ICAAC? Bad name, weirder pronunciation ("ick-kack"), ugly swag, and a classic case study in conference identity crisis. A look back—and where the big ID trials land now, which is #ESCMID Global, or whatever it's called. #IDSky blogs.jwatch.org/hiv-id-obser...

A reminder that SNAP results to be presented at #ESCMIDGlobal at: 'A trial run' 4.15-6.15 pm Hall 13 PSSA - (flu)clox vs benzylpenicillin MSSA - (flu)clox vs cefazolin LOTs of time for questions! Drinks right next to convention centre after: maps.app.goo.gl/Fc3WwH5aavrR...

Continuing with David Paterson keynote address #3 on AMR in Asia at #ESCMIDGlobal Need to do clinical trials in Asia. Where the infections are so prevalent. Sutton's law - go where the money is! Initiating TREAT-GNB platform trial

Continuing with David Paterson keynote address on AMR in Asia at #ESCMIDGlobal Three emerging threats in Asia! 1. Convergence of hypervirulence and AMR in K pneumo And it's being reported in US, Ukraine now. See EID 2025 April. If happening in Asia, will be spreading.

Continuing with David Paterson keynote address on AMR in Asia at #ESCMIDGlobal In Asia, often lack of access to newer antibiotics / combinations In Global burden of disease studies, the DALYs for GNBs collectively exceed any of TB, malaria, HIV, or dengue.

At David Paterson keynote address on AMR in Asia at #ESCMIDGlobal Another Australian front and centre Starts address by reflecting on one of his mentors, whose father Feng Shan Ho rescued 1000s of Jews from the Holocaust by issuing visas to Shanghai

Kalisvar MARIMUTHU at #ESCMIDGlobal Year in Infection control Browne Lancet ID 2024 RCT of enhanced cleaning of shared medical equipment (additional 3h per day) Clear drop in healthcare associated infections. 5% absolute reduction; 30% RRR Caveats: single centre, difficult to implement

Andrew Stewardson from Melbourne Australia presenting on a Year in Infection Control at #ESCMIDGlobal. @andrewstewardson.bsky.social #IDSky

Andrew Stewardson from Melbourne Australia presenting on a Year in Infection Control at #ESCMIDGlobal. @andrewstewardson.bsky.social #IDSky PICCs and PIVC studies

Andrew Stewardson from Melbourne Australia presenting on a Year in Infection Control at #ESCMIDGlobal. @andrewstewardson.bsky.social #IDSky WHO infection and control has released guidelines on pathogen transmission in air, catheters, infection control in facilities

Superb explanation of an important follow-up of the BALANCE trial. In depth explanation of ‘heterogeneity of treatment effect’ and finding that there was no discernible HTE in BALANCE. Read the thread, listen to Sean explain at ESCMID details below), and read the paper!